Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Rationale for 10-day decitabine with venetoclax for high-risk AML

Abhishek Maiti • 1 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia Decitabine Venetoclax

Abhishek Maiti, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the rationale behind a Phase II study investigating venetoclax and decitabine for relapsed/refractory acute myeloid leukemia (AML) patients (NCT03404193). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Abhishek Maiti

2:05
Venetoclax with decitabine for high-risk AML and MDS
Abhishek Maiti • 2 Jun 2020
9:17
Comparing outcomes of 10-day decitabine with venetoclax vs. chemotherapy in AML based on fitness
Abhishek Maiti • 2 Jun 2020
6:21
Decitabine and venetoclax for AML
Abhishek Maiti • 1 Jun 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals